“ERASE” Trial: Infusions of Reconstituted HDL Treat Atherosclerosis in Patients with Acute Coronary Syndromes

AudioMedica News
AudioMedica News
"ERASE" Trial: Infusions of Reconstituted HDL Treat Atherosclerosis in Patients with Acute Coronary Syndromes
Loading
/
Jean-Claude Tardif

JEAN-CLAUDE TARDIF, Montreal Heart Institute

REFERENCE: Abstract 405-10, American College of Cardiolgy New Orleans
Improvements in atheroma plaque have been achieved by infusing patients who have acute coronary syndromes with reconstituted high density lipoprotein, HDL, according to investigators from the Canada reporting to the American College of Cardiology annual meeting in New Orleans. Jean-Claude Tardif discussed his group’s findings from the ERASE trial in which they infused patients with a drug containing reconstituted HDL similar to the “baby” form of natural HDL.

[audio:https://www.audiomedica.com/podcasting/cardio/acc2007/070327_jean-claude_tardif.mp3]

Further reading

Sign up for AudioMedica.com news

* = required field
Speciality